Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Mersana Therapeutics, Inc.MRSN · Entity 69982 | Chief Medical Officer | February 02, 2018 | February 06, 2018 |
| Relay Therapeutics, Inc.RLAY · Entity 4044 | President, R&D | September 08, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Mersana Therapeutics, Inc.
Report date February 02, 2018 · Filed February 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.23 · Expires 2028-02-01 | Direct | 56,884 |
Reported balance
After 2018-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-02 · Grant · Acquired 56,884 · Balance 56,884 F1: The options vest in equal quarterly installments over the first four years after the vesting commencement date, February 2, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest in equal quarterly installments over the first four years after the vesting commencement date, February 2, 2018.
Relay Therapeutics, Inc.
Report date September 08, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 399,130 |
Reported balance
After 2026-09-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-08 · Sale · Disposed 8,530 · Balance 399,130 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2: This transaction was executed in multiple trades at prices ranging from $18.56 to $19.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3: Includes 10,025 shares underlying restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $18.56 to $19.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: Includes 10,025 shares underlying restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Fusion Pharmaceuticals Inc.
Report date June 04, 2024 · Filed June 04, 2024
Section 16 reporting ended · disclosed 2024-06-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.59 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-04 · Disposition to issuer · Disposed 34,000 · Balance 0 F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions. F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.60 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions.
F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2022 Filed Feb 23, 2022 02:01 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 12,242 | $20.94 | $256,347.48 |
DisclosureSEC source: 0001209191-22-011991 · doc4.xml · nonDerivative · entry 3 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,678 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $20.26 to $21.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 93,387 shares underlying restricted stock units. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 02:01 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 8,000 | $20.94 | $167,520.00 |
DisclosureSEC source: 0001209191-22-011991 · doc4.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,920 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $20.27 to $21.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 93,387 shares underlying restricted stock units. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 02:01 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 8,000 | $4.12 | $32,960.00 |
DisclosureSEC source: 0001209191-22-011991 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,920 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022. F2 · balance_after: Includes 93,387 shares underlying restricted stock units. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:17 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 129,900 | $0.00 Strike: $20.38 | $0.00 |
DisclosureSEC source: 0001209191-22-005662 · doc4.xml · derivative · entry 2 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,900 Underlying: Common Stock · 129,900 shares Expires 2032-01-26 F3 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 27, 2022, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:17 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 64,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005662 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,920 F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. The RSUs shall vest in sixteen (16) equal quarterly installments commencing on January 27, 2022, subject to the reporting person's continued service with the Issuer through each vesting date. F2 · balance_after: Includes 93,387 shares underlying RSUs. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 00:39 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 649 | $33.10 | $21,481.90 |
DisclosureSEC source: 0001209191-21-071312 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,970 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,188 shares of restricted stock units ("RSUs") on December 26, 2021. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 28,437 shares underlying RSUs. Read SEC document |
| October 15, 2021 Filed Oct 20, 2021 00:56 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 30,000 | $34.15 | $1,024,500.00 |
DisclosureSEC source: 0001209191-21-061088 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,619 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $33.309 to $36.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 27, 2021 Filed Sep 28, 2021 01:27 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 646 | $36.87 | $23,818.02 |
DisclosureSEC source: 0001209191-21-057860 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,619 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,187 shares of restricted stock units ("RSUs") on September 26, 2021. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 30,625 shares underlying RSUs. Read SEC document |
| June 28, 2021 Filed Jun 30, 2021 22:25 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 976 | $35.81 | $34,950.56 |
DisclosureSEC source: 0001209191-21-044062 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,265 F1 · shares: Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 2,187 shares of restricted stock units ("RSUs") on June 26, 2021. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. F2 · balance_after: Includes 32,812 shares underlying RSUs. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:38 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 42,242 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-21-041732 · doc4.xml · derivative · entry 3 Bergstrom Donald A · CIK 0001709772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,456 Underlying: Common Stock · 42,242 shares Expires 2028-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F3 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:38 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 42,242 | $33.75 | $1,425,667.50 |
DisclosureSEC source: 0001209191-21-041732 · doc4.xml · nonDerivative · entry 2 Bergstrom Donald A · CIK 0001709772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,241 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $33.09 to $34.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:38 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 42,242 | $4.12 | $174,037.04 |
DisclosureSEC source: 0001209191-21-041732 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. Read SEC document |
| June 04, 2021 Filed Jun 7, 2021 16:12 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001209191-21-038564 · doc4.xml · derivative · entry 1 Bergstrom Donald A · CIK 0001709772 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: This option fully vests on the earlier of (i) June 4, 2022 or (ii) the 2022 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 23:08 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 56,324 | $32.36 | $1,822,644.64 |
DisclosureSEC source: 0001209191-21-027638 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,241 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $31.59 to $33.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 16:20 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $10.59 | $0.00 |
DisclosureSEC source: 0001209191-21-024103 · doc4.xml · derivative · entry 1 Bergstrom Donald A · CIK 0001709772 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2031-04-01 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 36 substantially equal monthly installments starting on May 1, 2021. Read SEC document |
| March 26, 2021 Filed Mar 27, 2021 00:05 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 69,998 | $0.00 Strike: $34.25 | $0.00 |
DisclosureSEC source: 0001209191-21-023334 · doc4.xml · derivative · entry 2 Bergstrom Donald A · CIK 0001709772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,998 Underlying: Common Stock · 69,998 shares Expires 2031-03-25 F2 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments after March 26, 2021, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| March 26, 2021 Filed Mar 27, 2021 00:05 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 34,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023334 · doc4.xml · nonDerivative · entry 1 Bergstrom Donald A · CIK 0001709772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,565 F1 · shares: Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting. The RSUs shall vest in sixteen (16) equal quarterly installments after March 26, 2021, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 21:30 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 126,727 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001209191-20-063481 · doc4.xml · derivative · entry 1 Bergstrom Donald A · CIK 0001709772 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,727 Underlying: Common Stock · 126,727 shares Expires 2030-03-01 F1 · shares: On March 2, 2020, the reporting person was granted an option to purchase 126,727 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer has met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 31,682 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 95,045 shares, shall vest in sixteen (16) equal quarterly installments following March 11, 2021. Vesting of this option is subject to the reporting person's continued employment through each applicable vesting date. F1 · derivative.exercise_date: On March 2, 2020, the reporting person was granted an option to purchase 126,727 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer has met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 31,682 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 95,045 shares, shall vest in sixteen (16) equal quarterly installments following March 11, 2021. Vesting of this option is subject to the reporting person's continued employment through each applicable vesting date. F1 · derivative.underlying_shares: On March 2, 2020, the reporting person was granted an option to purchase 126,727 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer has met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 31,682 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 95,045 shares, shall vest in sixteen (16) equal quarterly installments following March 11, 2021. Vesting of this option is subject to the reporting person's continued employment through each applicable vesting date. F1 · balance_after: On March 2, 2020, the reporting person was granted an option to purchase 126,727 shares of common stock, subject to determination by the Board of Directors of the Issuer (the "Board") that the Issuer has met, in whole or in part, certain milestones (the "2020 Option Grant Criteria"). On June 23, 2020, the Board determined that the 2020 Option Grant Criteria related to 25% of the option had been achieved, and the shares underlying 25% of this option, or 31,682 shares, commenced vesting in sixteen (16) equal quarterly installments following September 23, 2020. On December 11, 2020, the Board determined that the 2020 Option Grant Criteria related to the remaining 75% of the option had been achieved. The shares underlying 75% of this option, or 95,045 shares, shall vest in sixteen (16) equal quarterly installments following March 11, 2021. Vesting of this option is subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| February 02, 2018 Filed Feb 6, 2018 21:24 UTC | Mersana Therapeutics, Inc. MRSN · Entity 69982 | GrantStock Option (right to buy) · Derivative | 56,884 | $0.00 Strike: $14.23 | $0.00 |
DisclosureSEC source: 0001104659-18-006855 · a4.xml · derivative · entry 1 Bergstrom Donald A · CIK 0001709772 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,884 Underlying: Common Stock · 56,884 shares Expires 2028-02-01 F1 · derivative.exercise_date: The options vest in equal quarterly installments over the first four years after the vesting commencement date, February 2, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.